Health Canada
GUIDANCE FINAL
Updated: Guidance on nitrosamine impurities in medications
Published: 11/5/2026Detected: 3/22/2026
Summary preview
Guidance on nitrosamine impurities in medications is updated, potentially tightening expectations for manufacturers to evaluate, control, and communicate nitrosamine-related risks across product quality systems.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from HEALTH CANADA.
More from Health Canada
- Advisory Committee: Review of the Federal Approach to Pandemic Science Advice and Research Coordination11/6/2026
- Advisory Committee: National Pharmacare Committee of Experts11/6/2026
- Advisory Committee: Ministerial Advisory Council on Mental Health11/6/2026
- Advisory Committee: Expert Task Force on Substance Use11/6/2026
- Advisory Committee: Expert Panel on MAID and Mental Illness11/6/2026